Nucleome Therapeutics
Nucleome Therapeutics technology uses novel molecular biology techniques that define the 3D structure of the genome and computational genomics powered by machine learning to help deliver the next generation of genetically guided therapeutics.
1
Funding Rounds
$86.4m
Money raised
Overview
Nucleome Therapeutics technology uses novel molecular biology techniques that define the 3D structure of the genome and computational genomics powered by machine learning to help deliver the next generation of genetically guided therapeutics.
-
Website:
- Business model: B2B
- Headquarters: Oxford
- Social accounts:
Funding series
Funding Series Analysis
The company Nucleome Therapeutics has raised a total of $42.35m in funding over 1 rounds.
Key Insights:
- Nucleome Therapeutics - Series A round, October 2022: $42.35m
Nucleome Therapeutics - Series A round, October 2022
$42.35m
Industries
Nucleome Therapeutics is active in the following industries: